MEDICARE PART D ENROLLEES' USE OF OUT-OF-PLAN DISCOUNTED GENERIC DRUGS, REVISITED RESPONSE

被引：2
|
作者：
Stuart, Bruce [1 ]
Loh, F. Ellen [1 ]
机构：
[1] Univ Maryland, Sch Pharm, Dept Pharmaceut Hlth Serv Res, Baltimore, MD 21201 USA
来源：
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY | 2013年 / 61卷 / 02期
关键词：
D O I：
10.1111/jgs.12080
中图分类号：
R592 [老年病学]; C [社会科学总论];
学科分类号：
03 ; 0303 ; 100203 ;
摘要：
引用
收藏
页码：310 / 310
页数：1
相关论文
共 50 条
  • [41] COMPARING OUT-OF-POCKET SPENDING ON ULTRA-EXPENSIVE DRUGS IN MEDICARE PART D AND THE COMMERCIALLY INSURED POPULATION
    DiStefano, M. J.
    Kang, S. Y.
    Parasrampuria, S.
    Anderson, G.
    VALUE IN HEALTH, 2023, 26 (06) : S219 - S219
  • [42] State laws and prescribing rates of generic drugs in dermatology: a cross-sectional analysis of 2020 Medicare Part D claims data
    Diaz, Michael Joseph
    Tran, Jasmine Thuy
    Forouzandeh, Mahtab
    ARCHIVES OF DERMATOLOGICAL RESEARCH, 2023, 315 (10) : 2991 - 2993
  • [43] State laws and prescribing rates of generic drugs in dermatology: a cross-sectional analysis of 2020 Medicare Part D claims data
    Michael Joseph Diaz
    Jasmine Thuy Tran
    Mahtab Forouzandeh
    Archives of Dermatological Research, 2023, 315 : 2991 - 2993
  • [44] Changes in Drug Use and Out-of-Pocket Costs Associated with Medicare Part D Implementation: A Systematic Review
    Polinski, Jennifer M.
    Kilabuk, Elaine
    Schneeweiss, Sebastian
    Brennan, Troyen
    Shrank, William H.
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2010, 58 (09) : 1764 - 1779
  • [45] The impact of the Medicare Part D donut hole closure on use and out-of-pocket costs for aromatase inhibitors
    Graetz, Ilana
    Anderson, Janeane N.
    Kaplan, Cameron M.
    CANCER RESEARCH, 2018, 78 (13)
  • [46] Specialty Drug Pricing and Out-of-Pocket Spending on Orally Administered Anticancer Drugs in Medicare Part D, 2010 to 2019
    Dusetzina, Stacie B.
    Huskamp, Haiden A.
    Keating, Nancy L.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2019, 321 (20): : 2025 - 2027
  • [47] HEALTH PLAN PERFORMANCE ON HIGH-RISK MEDICATION USE AMONG MEDICARE PART D BENEFICIARIES: IMPACT OF RISK ADJUSTMENT
    Chinthammit, C.
    Axon, D.
    Bhattacharjee, S.
    Slack, M.
    Lo-Ciganic, W.
    Bentley, J. P.
    Warholak, T.
    VALUE IN HEALTH, 2020, 23 : S304 - S304
  • [48] The Medicare Part D Coverage Gap: Drug Use and Adherence Among Patients With High Out-of-Pocket Expenditures
    Hsu, J.
    Price, M.
    Fung, V.
    Brand, R.
    Bertko, J.
    Newhouse, J.
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2010, 58 : 5 - 6
  • [49] Association of Rising Cost and Use of Oral Anticancer Drugs With Medicare Part D Spending From 2013 Through 2017
    Seiger, Kira
    Mostaghimi, Arash
    Silk, Ann W.
    Schmults, Chrysalyne D.
    Ruiz, Emily Stamell
    JAMA ONCOLOGY, 2020, 6 (01) : 154 - 156
  • [50] Changes in Use of Lipid-lowering Medications Among Black and White Dual Enrollees With Diabetes Transitioning From Medicaid to Medicare Part D Drug Coverage
    Adams, Alyce S.
    Madden, Jeanne M.
    Zhang, Fang
    Soumerai, Stephen B.
    Gilden, Dan
    Griggs, Jennifer
    Trinacty, Connie M.
    Bishop, Christine
    Ross-Degnan, Dennis
    MEDICAL CARE, 2014, 52 (08) : 695 - 703
12345